Skip to content

A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM

Effects of Time-restricted Eating on the Incidence of Gestational Diabetes Mellitus in High-risk Populations: a Randomized Controlled Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06431997
Enrollment
240
Registered
2024-05-29
Start date
2024-04-27
Completion date
2026-07-10
Last updated
2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Habits, Gestational Diabetes Mellitus, Lifestyle Intervention, Randomized Controlled Study

Keywords

Gestational Diabetes Mellitus, Metabolic Diseases

Brief summary

This is a randomized controlled trial, aiming to investigate whether a time-restricted eating (TRE) can reduce the incidence of gestational diabetes mellitus (GDM) in high-risk pregnant women. Investigators intend to conduct a 3-month randomized controlled study to compare the effects of 10-hour TRE and habitual eating time on GDM .

Detailed description

Investigators present a multicenter, open-label and parallel-group randomized study. Total 240 women in early pregnancy were randomly assigned to TRE group and SOC (standard of care) group according to the ratio of 1: 1. Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months. All participants should follow moderate-intensity physical activity for about 30 minutes every day, and receive diet and exercise counseling during the study period. GDM was diagnosed by 75g oral glucose tolerance test (OGTT) test at about 26 gestational weeks.

Interventions

BEHAVIORALTime-limited eating

All participants will be instructed to follow a diet of 1800-2200 kcal/d (50-60% of energy from carbohydrate, 30% from protein, 10-20% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.

Sponsors

Fudan University
Lead SponsorOTHER
Shenzhen Maternity & Child Healthcare Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 18-50 years; 2. The risk for GDM includes overweight or obesity (BMI ≥ 28 kg/m2 before pregnancy), first-degree relative with diabetes, history of cardiovascular disease, hypertension (≥130/80 mmHg or on therapy for hypertension), HDL cholesterol level \< 1 mmol/L and/or a triglyceride level \> 2.8 mmol/L, history of GDM, history of macrosomia delivery, individuals with polycystic ovary syndrome, repeated positive fasting urine glucose in the first trimester, or age\>45 years according to Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022); 3. Less than 14 weeks of gestation; 4. Able to read and complete questionnaires in Chinese; 5. singleton pregnancy.

Exclusion criteria

1. Pregestational diabetes (including diabetes diagnosed before conception; fasting blood glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5% in the first trimester; typical symptoms of hyperglycemia or hyperglycemic crisis with optional blood glucose ≥ 11.1 mmol/L); 2. Impaired glucose tolerance (including fasting blood glucose ≥ 5.6 mmol/L or two fasting blood glucose ≥ 5.1 mmol/L in the first trimester); 3. Current or recent use of drugs that affect glucose metabolism such as metformin, glucocorticoids and Orlistat; 4. Severe comorbidities (including cardiac diseases, kidney diseases, hepatopathy, autoimmune diseases, uncontrolled thyroid disease, previous or current malignant tumors, etc.); 5. Fetal malformations or chromosomal abnormalities; 6. Cervical insufficiency (including ultrasonic cervical length \< 25 mm before 24 weeks of gestation, history of spontaneous preterm birth at 14-36 weeks of previous pregnancy, or cervical dilation in the past or current pregnancy); 7. Exercise contraindications (including continuous vaginal bleeding, threatened premature labor, placenta previa, premature rupture of membranes, severe anemia, etc.); 8. Drug abuse, which refers to the repetitive, heavy use of drugs with dependent characteristics such as narcotic, psychotropic substances, tobacco and alcohol; 9. Hyperemesis gravidarum, which refers to the severe and persistent nausea and vomiting, unable to eat or eat little that leads to dehydration, ketosis and even acidosis; 10. On a special or prescribed diet for other reasons; 11. Eating window\<10 h; 12. Considered by the researchers to be ineligible for participation. Exit criteria: 1. Failure to comply with or assume the corresponding responsibilities and obligations of the informed agreement; 2. Pregnant women who terminate their pregnancy before completing GDM diagnosis and screening at 24-28 weeks of pregnancy will automatically withdraw from the group, such as severe fetal malformation, eclampsia, abortion, etc. 3. Major diseases, such as particularly serious obstetric medical events, malignant tumors, serious cardiovascular and cerebrovascular diseases, brain injuries, paralysis and other major diseases, can not continue to accept this intervention plan and follow-up, and withdraw from the study; 4. Accidental disability or death caused by non-intervention factors occurred during the study period, and he withdrew from the study; 5. Subjects are subjectively unwilling to continue to accept the intervention program, and sign the withdrawal agreement to withdraw from the group on a voluntary basis, and decide whether to continue to follow up the pregnancy process and outcome according to the specific contents of the withdrawal statement.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of GDM26 gestational weeksDiagnosed by the 75g oral glucose tolerance test (OGTT).

Secondary

MeasureTime frameDescription
Number of newborns with macrosomiaAt deliveryNumber of newborns with birth weight ≥4000g.
Number of newborns with low birth weightAt deliveryNumber of newborns with birth weight \<2500g.
Number of newborns large for gestational age (LGA)At deliveryNumber of newborns with weight lies above the 90th percentile for the gestational age.
Number of newborns small for gestational age (SGA)At deliveryNumber of newborns with weight lies below the 10th percentile for the gestational age.
Incidence of shoulder dystociaAt deliveryThe incidence of the condition in which normal traction on the fetal head does not lead to the delivery of the shoulders.
Number of newborns with birth injuryAt deliveryNumber of newborns with an impairment of the neonate's body function or structure due to an adverse event that occurred at birth.
Number of neonatus with neonatal intensive care unit (NICU) admissionWithin the first 28 days after deliveryNumber of neonatus with neonatal intensive care unit (NICU) admission.
Number of neonatus with neonatal respiratory distressWithin the first 28 days after deliveryNumber of neonatus with clinical symptoms including tachypnea, nasal flaring, grunting, retractions (subcostal, intercostal, supracostal, jugular), cyanosis, apnea, bradypnea, irregular breathing, inspiratory stridor, wheeze and hypoxia, etc.
Number of neonatus with hypoglycemiaWithin the first 48 hours after deliveryNumber of neonatus with venous glucose levels \<2.6mmol/L.
Number of neonatus with pathologic jaundiceWithin the first 28 days after deliveryJaundice that arises from factors that alter the usual process involved in bilirubin metabolism in the liver that requires treatment.
Number of neonatus with intraventricular hemorrhage (IVH) of II grade or aboveWithin the first 28 days after deliveryIntraventricular hemorrhage (IVH) of II grade or above diagnosed by ultrasound.
Number of neonatus with necrotizing enterocolitis (NEC)Within the first 28 days after deliveryNecrotizing enterocolitis (NEC) diagnosed by radiography or surgery.
Number of neonatus managed with assisted ventilation >24 hours via endotracheal tube.Within 72 hours of birthNumber of neonatus managed with assisted ventilation \>24 hours via endotracheal tube.
Number of neonatus with sepsis.Within the first 28 days after deliveryNumber of neonatus with septicemia ascertained by blood culture.
The incidence of neonatal death.Within the first 28 days after deliveryThe incidence of deaths among live births during the first 28 completed days of life.
The level of maternal fasting plasma insulinat 24-28 gestational weeksMaternal fasting plasma insulin level.
The level of maternal HbA1cat 24-28 gestational weeksMaternal venous glycosylated hemoglobin A1c (HbA1c) level.
Insulin resistance calculated by homeostatic model assessment (HOMA-IR)at 24-28 gestational weeksInsulin resistance calculated by homeostatic model assessment (HOMA-IR). HOMA-IR=fasting plasma glucose (FPG)× fasting plasma insulin (FINS)/22.5. The higher HOMA-IR value indicates higher severity of insulin resistance.
Maternal lipid profileat 24-28 gestational weeksLevel of maternal venous low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and total cholesterol.
Maternal change in depression, quality of sleep and quality of lifeFrom pre-pregnancy to 24-28 gestational weeksMaternal change in depression, quality of sleep and quality of life measured by the Patient Health Questionnaire-9 (PHQ-9), Pittsburgh sleep quality index (PSQI) and 12-item Short-Form Health Survey Questionnaire (SF-12) according to pre-pregnancy status and 24-28 gestational weeks. The Patient Health Questionnaire-9 (PHQ-9): Scores range from 0 to 27, with higher scores indicating severer depression. The standard cut-off score for screening to identify possible major depression is 10 or above. Pittsburgh sleep quality index (PSQI): Scores range from 0 to 21, with higher scores indicating worse sleep quality. 12-item Short-Form Health Survey Questionnaire (SF-12): physical component score (PCS) range from 0 to 100, higher scores are better.
Gestational weight gainFrom pre-pregnancy to 24-28 gestational weeksMeasured according to pre-pregnancy weight and weight at 24-28 gestational weeks.
Change in waist circumferenceFrom pre-pregnancy to 24-28 gestational weeksMeasured according to pre-pregnancy waist circumference and waist circumference at 24-28 gestational weeks.
Incidence of maternal morbiditiesFrom 24-28 gestational weeks to deliveryIncidence of hypertensive disorders of pregnancy, hydramnios, placental abruption, preterm/prelabor rupture of membranes (P/PROM), preterm birth, chorioamnionitis, postpartum hemorrhage and still birth.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026